A Brain Cancer Vaccine?

Print Friendly, PDF & Email
A new vaccine is designed to help train immune cells to target a mutation unique to brain tumors
A new vaccine is designed to help train immune cells to target a mutation unique to brain tumors

A new article published in the journal Nature is reporting promising results from a landmark Phase 1 human trial testing a novel vaccine designed to help a patient’s immune system better target brain tumors. The data suggests the experimental vaccine is safe and stimulates a significant immune response that slows tumor progression. A larger Phase 2 trial is currently being planned.

Diffuse gliomas are a particularly difficult kind of brain cancer to treat. They can spread across the brain making it difficult to easily eliminate them through traditional surgery, but these tumors do often share a common feature – over 70 percent of low-grade gliomas have a single gene mutation affecting an enzyme called isocitrate dehydrogenase 1 (IDH1).

This IDH1 mutation is unique to gliomas and leads to the creation of novel proteins called neo-epitopes. Michael Platten, from the German Cancer Research Center, has been working for years to create a vaccine that helps a patient’s immune system learn to target these IDH1 mutated cells.

 

About the Common Constitutionalist

Brent, aka The Common Constitutionalist, is a Constitutional Conservative, and advocates for first principles, founders original intent and enemy of progressives. He is former Navy, Martial Arts expert. As well as publisher of the Common Constitutionalist blog, he also is a contributing writer for Political Outcast, Godfather Politics, Minute Men News (Liberty Alliance), Freedom Outpost, the Daily Caller, Vision To America and Free Republic. He also writes an exclusive weekly column for World Net Daily (WND).